Elevation Oncology Inc. (NASDAQ: ELEV)
$0.5646
-0.0089 ( -2.66% ) 433.0K
Elevation Oncology Inc is an oncology company focused on the development of targeted therapeutics for the treatment of cancer in genomically defined patient populations. Its lead program is focused on neuregulin-1, or NRG1, fusions, which are rare genomic alterations that have the potential to be therapeutically actionable through targeted HER3 inhibition.
Market Data
Open
$0.5646
Previous close
$0.5735
Volume
433.0K
Market cap
$33.67M
Day range
$0.5500 - $0.5930
52 week range
$0.4401 - $5.8299
SEC Filings
Form Type | Description | Pages | Date |
---|---|---|---|
ars | Annual reports | 1 | Apr 26, 2024 |
def | Proxies and info statements | 4 | Apr 26, 2024 |
8-k | 8K-related | 15 | Apr 05, 2024 |
4 | Insider transactions | 1 | Mar 19, 2024 |
10-k | Annual reports | 98 | Mar 06, 2024 |
8-k | 8K-related | 16 | Mar 06, 2024 |
4 | Insider transactions | 1 | Mar 04, 2024 |
4 | Insider transactions | 1 | Mar 04, 2024 |
3 | Insider transactions | 2 | Mar 04, 2024 |
3 | Insider transactions | 2 | Mar 04, 2024 |